

REPORT DOCUMENTATION PAGEForm Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)

2. REPORT DATE

March 2003

3. REPORT TYPE AND DATES COVERED

Final (1 Mar 00 - 28 Feb 03)

4. TITLE AND SUBTITLE

COX-2 and Prostate Cancer Angiogenesis

5. FUNDING NUMBERS

DAMD17-00-1-0090

6. AUTHOR(S):

Alice C. Levine, M.D.

20040223 117

7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)

Mount Sinai School of Medicine
New York, New York 10029E-Mail: alice.levine@mssm.edu8. PERFORMING ORGANIZATION
REPORT NUMBER

9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)

U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-501210. SPONSORING / MONITORING
AGENCY REPORT NUMBER

11. SUPPLEMENTARY NOTES

Original contains color plates: All DTIC reproductions will be in black and white.

12a. DISTRIBUTION / AVAILABILITY STATEMENT

Approved for Public Release; Distribution Unlimited

12b. DISTRIBUTION CODE

13. Abstract (Maximum 200 Words) (abstract should contain no proprietary or confidential information)

Cyclooxygenase-2 (COX-2) is an inducible enzyme which catalyzes the conversion of arachidonic acid to prostaglandins and has previously been demonstrated to play a role in carcinogenesis. We demonstrated that COX-2 and one of its major prostaglandin products, PGE₂, are mediators of hypoxia-induced increases in a potent angiogenic factor, VEGF, in a human prostate cancer cell line. In these studies we determined (1) The optimal dosing and timing of administration of a COX-2 inhibitor (NS-398) in an animal model of prostate cancer (2) and (3) the mechanisms underlying the observed effects of COX-2 and PGE₂ on hypoxia-induced upregulation of VEGF and tumor angiogenesis. Over the past year, we have completed our *in vivo* studies and determined that NS-398 inhibits prostate tumor growth significantly, whether it is given before or after tumor cell inoculation. We also completed our studies demonstrating that PGE₂ induces the protein expression of a central regulator of hypoxic effects, hypoxia-inducible factor-1 α (HIF-1 α) and induces its nuclear localization. Our data indicates that NS-398 blocks hypoxic effects on HIF-1 α protein while PGE₂ restores hypoxic effects, even in the presence of NS-398. Several kinase pathways are involved in PGE₂ effects on HIF-1 α protein stabilization.

14. SUBJECT TERMS:

angiogenesis, VEGF, COX-2

15. NUMBER OF PAGES

16

16. PRICE CODE

17. SECURITY CLASSIFICATION
OF REPORT

Unclassified

18. SECURITY CLASSIFICATION
OF THIS PAGE

Unclassified

19. SECURITY CLASSIFICATION
OF ABSTRACT

Unclassified

20. LIMITATION OF ABSTRACT

Unlimited

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89)
Prescribed by ANSI Std. Z39-18
298-102

AD _____

Award Number: DAMD17-00-1-0090

TITLE: COX-2 and Prostate Cancer Angiogenesis

PRINCIPAL INVESTIGATOR: Alice C. Levine, M.D.

CONTRACTING ORGANIZATION: Mount Sinai School of Medicine
New York, New York 10029

REPORT DATE: March 2003

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

Table of Contents

Cover.....	1
SF298.....	2
Table of Contents.....	3
Introduction.....	4
Body.....	5-6
Key Research Accomplishments.....	7
Reportable Outcomes.....	8
Conclusions.....	9
References.....	10
Appendices.....	11-16
	(one reprint, 6 pages)

INTRODUCTION

Cyclooxygenase-2 (COX-2) is an inducible enzyme which catalyzes the conversion of arachidonic acid to prostaglandins. COX-2 plays a key role in cancer (1-4) and COX-2 inhibition prevents and treats colon cancer (5-7). Both COX-2 and its major derived prostaglandin product (PGE₂) have been implicated as stimulators of tumor angiogenesis (8-13).

We previously demonstrated that COX-2 expression is increased in human prostate cancer tissues (14) and that a COX-2 inhibitor selectively induces apoptosis in a prostate cancer cell line (15). We also demonstrated that treatment of human prostate tumor-bearing mice with a selective COX-2 inhibitor (NS-398) significantly reduces tumor size, microvessel density and levels of a potent tumor angiogenic factor, vascular endothelial growth factor (VEGF) (16).

Our *in vitro* studies with a highly invasive human prostate cancer cell line, PC-3ML, demonstrated that cobalt-chloride simulated hypoxia induced VEGF upregulation. In that same report, VEGF upregulation by cobalt chloride simulated hypoxia was prevented by NS-398 treatment and restored by the addition of PGE₂ (one of the major prostaglandin products of the reaction catalyzed by COX-2) (17).

Based on our preliminary data, we hypothesized that COX-2 and the resultant PGE₂ are mediators of hypoxia-induced effects on VEGF in prostate cancer cells (18). We further hypothesized that PGE₂ mediates hypoxic upregulation of VEGF by modulating hypoxia-inducible factor-1 α (HIF-1 α), the major transcriptional regulator of VEGF expression. The first task of our initial proposal was to determine the optimal dosing and timing of administration of NS-398 (COX-2 inhibitor) in prostate-tumor bearing mice. The second task was to determine the mechanisms underlying the observed effects of the COX-2 inhibitor and PGE₂ on hypoxia-induced upregulation of VEGF. Specifically, we originally proposed to determine whether PGE₂ itself regulates HIF-1 α and VEGF expression levels. Finally, in Task 3, studies were proposed to determine whether PGE₂ modulates VEGF transcription by enhancing the binding of HIF to the promoter region of the VEGF gene.

Task 1. Perform studies using a mouse model of human prostate cancer to determine the *in vivo* efficacy of a selective COX-2 inhibitor as an anti-tumor and anti-angiogenic agent.

Our initial studies indicated that maximal inhibition of tumor growth was achieved with the highest dose of a selective COX-2 inhibitor (NS-398) (3.0 mg/kg/body weight administered three times weekly, intraperitoneally, for a total of 12 weeks, beginning two weeks after tumor cell inoculation). In last year's report, we had begun studies testing the effects of NS-398 given prior to tumor cell inoculation. Over this past year, we have completed the *in vivo* studies and compared the effects of the drug when given prior to vs. after tumor cell inoculation.

1B. Optimal Timing of Drug Therapy

We compared the effect of NS398 given prior to vs. after tumor cell inoculation on the growth rates of PC-3 ML prostate tumor cells in nude mice. As demonstrated (Figure 1), NS-398 was given at a dose of 3 mg/kg body weight (optimal dose as demonstrated in previous studies) beginning either two weeks prior to tumor cell inoculation or two weeks after tumor cell inoculation. The three groups of nude mice (10 animals per group) were (1) Vehicle alone (Control) (2) NS-398 beginning two weeks prior to tumor cell inoculation and (3) NS-398 beginning two weeks after tumor cell inoculation. As demonstrated below, there was no difference in tumor take rates among the three groups. However, both pretreatment and posttreatment with NS-398 dramatically reduced tumor cell growth rates throughout the twelve week experimental time period. There were, however, no differences in the growth rates between the pretreatment and posttreatment NS-398 groups. These data indicate that a selective COX-2 inhibitor significantly reduces PC-3 ML tumor growth *in vivo*, and the timing of treatment initiation does not alter this effect.




Fig. 1: Effect of NS-398 pre- or post-treatment on PC-3 ML cell tumor growth in nude mice. Mice were randomly divided into three groups with 10 mice each. The first group of mice received vehicle (PBS) only as a control. The second group of mice received NS398 two weeks prior to tumor cell inoculation. The third group of mice received NS398 two weeks after tumor cell inoculation. NS398 was administered at a dose of 3 mg/kg/body weight three times weekly, intraperitoneally. The treatment was continued for the entire experimental period. Data are expressed as mean \pm SE.

Task 2: Determine the interactive effects of hypoxia, COX-2 and PGE₂ on HIF-1 α protein expression and nuclear localization.

In the previous annual reports (2001 and 2002), we demonstrated that true hypoxia increases VEGF secretion by PC-3ML human prostate cancer cells and that a COX-2 inhibitor (NS398) blocks this hypoxic effect, while co-administration of one of the COX-2 derived prostaglandin products (PGE₂) restores hypoxic effects on VEGF, even in the presence of NS-398. We further demonstrated that PGE₂ did not modulate HIF-1 α mRNA transcription but, rather, modulated HIF-1 α expression at the protein level. Last year we reported on the interactive effects of hypoxia, COX-2 and PGE₂ on HIF-1 α protein expression and nuclear localization. In addition, we investigated the possible kinase pathways that may be involved in nuclear localization and activation of HIF-1 α induced by both hypoxia and PGE₂.

We completed these studies over this past, final year of funding and have reported our findings in the Journal of Biological Chemistry 277:50081-50086, 2002 (Reference 19, APPENDIX, Reprints). To summarize our findings:

- 1) PGE₂ addition to PC-3ML human prostate cancer cells had no effect on mRNA levels of hypoxia-inducible factor (HIF).
- 2) PGE₂ addition to PC-3 ML cells, did significantly increase HIF-1 α protein levels, and specifically induced the nuclear localization of this important mediator of hypoxia effects.
- 3) Two selective COX-2 inhibitors, meloxicam and NS-398, decreased HIF-1 α levels and nuclear localization, under both normoxic and hypoxic conditions, in these cancer cells.
- 4) Of several prostaglandins tested, only PGE₂ reversed the effects of a COX-2 inhibitor in hypoxic cells.
- 5) PGE₂ effects on HIF-1 α were specifically inhibited by PD98059 (a MAP kinase inhibitor).

Task 3: Examine the intracellular interactions between PGE₂, HIF-1 α , and VEGF in PC-3 ML prostate cancer cells.

These studies were performed over this past year (final year) of funding. In vitro experiments were designed to test whether PGE₂ addition modulated the binding of HIF-1 to the VEGF promoter. Gel shift assays were performed with essentially negative results. That is, PGE₂ addition did not alter the binding of HIF to the VEGF promoter in these cells. We conclude that the PGE₂ (and COX-2) effects in this experimental system occur at the level of HIF protein expression and nuclear localization and do not occur via effects on HIF binding to the VEGF promoter.

KEY RESEARCH ACCOMPLISHMENTS

Over the entire funding period (3 years) of this project, we have demonstrated that

- A selective COX-2 inhibitor, NS398, dramatically decreases PC-3 ML prostate cancer tumor growth in a nude mouse model. We have determined the optimal dose (3 mg/kg/body weight given intraperitoneally twice weekly) and have also demonstrated that the effects are equal, whether the NS398 treatment is initiated two weeks prior to or two weeks after tumor cell inoculation. There was no observable toxicity of this treatment, given up to 15 weeks.
- Demonstrated that PGE₂ increases HIF-1 α protein levels in PC-3 ML prostate cancer cells.
- Demonstrated that PGE₂ induces nuclear localization of HIF-1 α protein in PC-3 ML cells.
- Elucidated the kinase pathways involved in the observed PGE₂ effects on HIF-1 α protein.
- Demonstrated that a COX-2 inhibitor specifically blocks the induction of HIF-1 α protein by hypoxia and that PGE₂ can restore this effect of hypoxia.

REPORTABLE OUTCOMES

Publications

Liu X.H., Kirschenbaum A., Lu M., Yao S., Dosoretz A., Holland J.F., and Levine A.C.: Prostaglandin E₂ Induces Hypoxia-Inducible Factor-1 α Stabilization and Nuclear Localization in a Human Prostate Cancer Cell Line. *Journal of Biological Chemistry* 277:50081-50086, 2002 (Reference 19, Appendix)

Kirschenbaum A., Liu X-H, Yao S., and Levine A.C.: The role of cyclooxygenase-2 in prostate cancer. *Urology (Supple 2A)*: 127-131, 2001 (Reference 18).

Presentations

Dr. Alice Levine (P.I.) was an invited speaker at two National Meetings and reported some of the findings of the DOD-funded studies in her talks.

"The Role of Cox-2 in Prostate Cancer", Alzheimer's Disease, Cancer and the Search for a Better Aspirin, New York, NY June 2001.

"Cox-2 Inhibitors as Anti-Angiogenic Therapy", Fourth International Symposium on Anti-Angiogenic Agents, Dallas, Texas, January 2002.

Funding Applied For Based On Work Supported by This Award

We are currently applying for a DOD grant (due date April 16, 2003) which would be a continuation of our findings. The new proposal will investigate the interactions between the p53 and KLF-6 tumor suppressor proteins and the COX-2/HIF system in prostate cancer.

CONCLUSIONS

Task 1: In Vivo Studies with NS-398 (COX-2 Inhibitor)

We have demonstrated that a selective COX-2 inhibitor, NS-398, is effective anti-tumor therapy in a nude mouse model of human prostate cancer. The highest dose utilized (3mg/kg/body weight given intraperitoneally three times weekly for 15 weeks) dramatically slowed tumor growth without any evidence of toxicity in the animals. We have further demonstrated that NS-398 is effective regardless of the timing of initiation of treatment (2 weeks prior to tumor cell inoculation or two weeks after tumor cell inoculation). There was no observable toxicity of this treatment in a 15 week experimental protocol.

Task 2: Determine the Interactive Effects of Hypoxia, COX-2 and PGE₂ on HIF-1 α Protein Expression and Nuclear localization

We studied the regulation of HIF-1 α protein levels and nuclear localization. As HIF-1 α is a nuclear transcriptional factor (involved in the transcriptional activation of a variety of hypoxia-induced genes), its nuclear localization is a key step in its activation.

We demonstrated (reference 19, Appendix) that PGE₂ increases HIF-1 α protein levels and induces its nuclear localization in PC-3 ML human prostate cancer cells. In addition, we demonstrated that several kinase pathways, most notably the MAP kinase pathway, mediate this effect. Finally, we demonstrated that COX-2 and PGE₂ mediate hypoxic effects on HIF-1 α protein and that a selective COX-2 inhibitor can prevent hypoxic upregulation of HIF-1 α protein in human prostate cancer cells.

These observations have important clinical applications in prostate cancer therapy. Intratumoral hypoxia cannot be controlled. Most hypoxic signaling occurs via HIF. We have demonstrated that a selective COX-2 inhibitor can prevent the upregulation of this central hypoxic signaling factor. Therefore, at least in this human prostate cancer cell line, COX-2 inhibition may prevent hypoxic upregulation of a variety of HIF-controlled genes including VEGF and glycolytic enzymes and thereby inhibit tumor growth and angiogenesis.

Task 3: Examine the intracellular interactions between PGE₂, HIF-1 and VEGF in PC-3 ML prostate cancer cells.

Our in vitro studies failed to demonstrate any effect of PGE₂ on the binding of HIF-1 α to the VEGF promoter region in PC-3 ML cells. We therefore conclude that the observable effects of PGE₂ and COX-2 inhibitors in this system are due to effects on HIF-1 α protein expression and nuclear localization.

OVERALL CONCLUSIONS: We demonstrated that PGE₂ production via the COX-2 catalyzed pathway plays a critical role in HIF-1 α regulation by hypoxia in human prostate cancer cells. These data imply that COX-2 inhibitors can prevent hypoxic induction of HIF-mediated gene transcription in cancer cells. As HIF is the master oxygen sensor and generally induces an angiogenic, apoptosis-resistant phenotype in hypoxic tumor cells, these findings may have important implications in the treatment of prostate cancer.

REFERENCES

1. Simmons D.L., Levy D.B., Yannoni Y., and Erikson, R.L. Identification of a phorbol ester-repressible *v-src*-inducible gene. *Proc. Natl. Acad. Sci. USA.* 86:1178-1182, 1989.
2. Kujubu, D.A., Flecher, B.S., Varnum B.C., Lim R.W., and Herschman H.R. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells encodes a novel prostaglandin synthase/cyclooxygenase homologue. *J. Biol. Chem.* 166:12866-12872, 1991.
3. Tsujii M. and DuBois R.N. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. *Cell.* 83:493-501, 1995.
4. Sheng H.M., Shao J.Y., Morrow J.D., Beauchamp R.D. and DuBois R.N. Modulation of apoptosis and bcl-2 expression by prostaglandin E2 in human colon cancer cells. *Cancer Res.* 58:362-366, 1998.
5. DuBois R.N., Giardello F.M. and Smalley W.E. Nonsteroidal anti-inflammatory drugs, eicosanoids and colorectal cancer prevention. *Gastroenterol. Clin. N. Am.* 25:773-791, 1996.
6. Sheng H., Shao J., Kirkland S.C., Isakson P., Coffey R., Morrow J., Beauchamp R.D. and DuBois R.N. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. *J. Clin. Invest.* 99:2254-2259, 1997.
7. Kawamori T., Rao C.V., Seibert K., and Reddy B.S. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. *Cancer Res.*, 58:409-412, 1998.
8. Auerbach, R. Angiogenesis-inducing factors: a review. In: Pick E., Ed., *Lymphokines*. New York, Academic Press, Vol 4:page 69, 1981
9. Folkman J. and Shing Y. Angiogenesis (Minireview). *J. Biol. Chem.* 267:10931-34, 1992.
10. Bicknell R., and Harris A.L. Novel growth regulatory factors and tumor angiogenesis. *Eur. J. Cancer* 27:781-785, 1991.
11. BenAv, P., Crofford L.J., Wilder R.L. and Hla T. Induction of VEGF expression in synovial fibroblasts by PGE and IL-1: a potential mechanism for inflammatory angiogenesis. *FEBS Lett.* 372:83-87, 1995.
12. Form D.M. and Auerbach R. PGE2 and angiogenesis. *Proc. Soc. Exp. Biol. Med.* 172:214-218, 1983.
13. Spisni E., Manica F., and Tomasi V. Involvement of prostanoids in the regulation of angiogenesis by polypeptide growth factors. *Prostaglandins, Leukotrienes, Essential Fatty Acids* 47:111-115, 1992.
14. Kirschenbaum A., Klausner A.P., Lee R., Unger P., Yao S., Liu X.H., and Levine A.C. Expression of cyclooxygenase-1 and cyclooxygenase-2 in the human prostate. *Urology* 56:671-676, 2000.
15. Liu X.-H., Yao S., Kirschenbaum A., and Levine A.C. NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells. *Cancer Res.* 58:4245-4249, 1998.
16. Liu X.-H., Kirschenbaum A., Yao S., Lee R., Holland J.F. and Levine A.C. Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer cells in vivo. *J. Urology* 164:820-825, 2000.
17. Liu X.-H., Kirschenbaum A., Yao S., Stearns M.E., Holland J.F., Claffey K., and Levine A.C. Upregulation of vascular endothelial growth factor by cobalt chloride-simulated hypoxia is mediated by persistent induction of cyclooxygenase-2 in a metastatic human prostate cancer cell line. *Clinical and Experimental Metastasis* 17:687-694, 1999
18. Kirschenbaum A., Liu X-H, Yao S. and Levine A.C. The role of cyclooxygenase-2 in prostate cancer. *Urology* 58 (Suppl 2A): 127-131, 2001.
19. Liu X.H., Kirschenbaum A., Lu M., Yao S, Dosoretz A., Holland J.F., and Levine A.C.: Prostaglandin E₂ induces hypoxia-inducible factor-1 α stabilization and nuclear localization in a human prostate cancer cell line. *Journal of Biol. Chem.*, 277:50081-50086, 2002.

Prostaglandin E₂ Induces Hypoxia-inducible Factor-1 α Stabilization and Nuclear Localization in a Human Prostate Cancer Cell Line*

Received for publication, February 1, 2002, and in revised form, October 17, 2002
Published, JBC Papers in Press, October 24, 2002, DOI 10.1074/jbc.M201095200

Xin Hua Liu[‡], Alexander Kirschenbaum, Min Lu, Shen Yao, Amy Dosoretz, James F. Holland, and Alice C. Levine

From the Department of Medicine, Mount Sinai School of Medicine, New York, New York 10029

Hypoxia-induced up-regulation of vascular endothelial growth factor (VEGF) expression is a critical event leading to tumor neovascularization. Hypoxia stimulates hypoxia-inducible factor-1 α (HIF-1 α), a transcriptional activator of VEGF. Cyclooxygenase (COX)-2, an inducible enzyme that catalyzes the formation of prostaglandins (PGs) from arachidonic acid, is also induced by hypoxia. We reported previously that COX-2 inhibition prevents hypoxic up-regulation of VEGF in human prostate cancer cells and that prostaglandin E₂ (PGE₂) restores hypoxic effects on VEGF. We hypothesized that PGE₂ mediates hypoxic effects on VEGF by modulating HIF-1 α expression. Addition of PGE₂ to PC-3ML human prostate cancer cells had no effect on HIF-1 α mRNA levels. However, PGE₂ significantly increased HIF-1 α protein levels, particularly in the nucleus. This effect of PGE₂ largely results from the promotion of HIF-1 α translocation from the cytosol to the nucleus. PGE₂ addition to PC-3 ML cells transfected with a GFP-HIF-1 α vector induced a time-dependent nuclear accumulation of the HIF-1 α protein. Two selective COX-2 inhibitors, meloxicam and NS398, decreased HIF-1 α levels and nuclear localization, under both normoxic and hypoxic conditions. Of several prostaglandins tested, only PGE₂ reversed the effects of a COX-2 inhibitor in hypoxic cells. Finally, PGE₂ effects on HIF-1 α were specifically inhibited by PD98059 (a MAPK inhibitor). These data demonstrate that PGE₂ production via COX-2-catalyzed pathway plays a critical role in HIF-1 α regulation by hypoxia and imply that COX-2 inhibitors can prevent hypoxic induction of HIF-mediated gene transcription in cancer cells.

It is well established that all tumors require the growth of new blood vessels, a process termed angiogenesis, in order to grow beyond 1–2 mm, invade, and metastasize (1). One of the major regulatory factors involved in neovascularization is vascular endothelial growth factor (VEGF).¹ Intratumoral hypoxia is a potent VEGF inducer in solid tumors. Hypoxic regulation of

VEGF is mediated by hypoxia-inducible factor-1 α (HIF-1 α), a key transcription factor that regulates cellular responses to physiological and pathological hypoxia (2). The VEGF gene contains a number of HIF-1 α -binding sites in its regulatory region, and HIF-1 α is able to activate the VEGF promoter (3). Deletion of the HIF-1 α gene or disruption of HIF-1 α transcription results in the lack of VEGF secretion by tumor cells, suppression of angiogenesis, and inhibition of solid tumor growth (4, 5). In response to hypoxia, HIF-1 α protein accumulates in the cytosol and translocates to the nucleus (6), where it activates hypoxia-sensitive genes, like VEGF, by binding to their promoter/enhancer regions (2). HIF-1 α -mediated up-regulation of VEGF, therefore, has been proposed as an angiogenic switch during tumorigenesis (7).

Hypoxic effects on HIF-1 α occur mainly at the post-translational level, as HIF-1 α mRNA levels are not significantly modified by hypoxia (2). Under normoxic conditions, HIF-1 α protein is rapidly degraded via the von Hippel-Lindau (VHL)-ubiquitin-proteasome pathway (8). The VHL protein recognizes the oxygen degradation domain of HIF-1 α protein only under normoxic conditions (9). In addition to hypoxia, a variety of factors have recently been demonstrated to be regulators of HIF-1 α expression, including reactive oxygen species, nitric oxide, cytokines, and growth factors (10). The regulation of HIF-1 α by hypoxia as well as these other factors involves the activation of phosphoinositol 3-kinase (PI3K)/AKT pathway (10) and/or phosphorylation by p42/p44 MAP kinase (10–13).

Cyclooxygenase (COX), also referred to as prostaglandin endoperoxide synthase, is a key enzyme in the conversion of arachidonic acid to prostaglandins (PGs) and other eicosanoids. Two isoforms of COX have been identified. COX-1 is expressed constitutively in many tissues and cell types, whereas COX-2 is inducible by a variety of factors, including cytokines, growth factors, and tumor promoters. COX-2 is highly expressed in a number of human cancers and cancer cell lines, including prostate cancer (14–16). Recent reports (17) have demonstrated that COX-2 expression and activity are induced by hypoxia in human umbilical vein endothelial cells, and this induction is not mediated by HIF-1 α but rather by the nuclear factor κ B transcription factor. Forced overexpression of COX-2 in a colon cancer cell line results in the overproduction of several pro-angiogenic factors, including VEGF (18). In addition, prostaglandin E₂ (PGE₂), a major end product of the COX-2-catalyzed reaction, is reported to be a stimulator of angiogenesis (19).

We demonstrated that inhibition of COX-2 suppresses prostate cancer growth and angiogenesis *in vivo*. Tumors treated with a COX-2 inhibitor were smaller, with increased apoptosis, decreased microvessel density, and decreased tumor VEGF

* This work was supported by Department of Defense Grant-in-aid DAMD 17-00-1-0090 and the T. J. Martell Foundation for Leukemia, Cancer, and Aids Research. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

[‡] To whom correspondence should be addressed: Dept. of Medicine, Box 1055, Annenberg Bldg., Rm. 23-78, Mount Sinai School of Medicine, One Gustave L. Levy Place, New York, NY 10029. Tel.: 212-241-4130; Fax: 212-241-4218; E-mail: liux01@doc.mssm.edu.

¹ The abbreviations used are: VEGF, vascular endothelial growth factor; COX, cyclooxygenase; PG, prostaglandin; HIF, hypoxia-inducible factor; MAP, mitogen-activated protein; MAPK, mitogen-activated protein kinase; Erk, extracellular signal-regulated kinase; GFP, green

fluorescent protein; PI3K, phosphoinositol 3-kinase; PBS, phosphate-buffered saline; Rt, reverse transcriptase; VHL, von Hippel-Lindau; RT, reverse transcriptase.

levels (20). Our *in vitro* studies demonstrated that the administration of a selective COX-2 inhibitor, NS398, prevented the effects of cobalt chloride-simulated hypoxia on VEGF up-regulation in PC-3ML human prostate cancer cells. In that same report, PGE₂ administration restored the effects of cobalt chloride on VEGF in the presence of the COX-2 inhibitor (21). Similar results have recently been observed when the same cell line was exposed to true hypoxia (1% O₂).²

We concluded that COX-2 and PGE₂ are involved in the hypoxic induction of VEGF. We hypothesized that the effects of COX-2 and PGE₂ on hypoxia-induced VEGF are mediated by the regulation of HIF-1 α expression and activation in PC-3ML human prostate tumor cells. In this report, we demonstrate that PGE₂ has no effect on HIF-1 α mRNA expression. However, PGE₂, under normoxic conditions, promotes HIF-1 α protein stabilization, particularly in the nucleus. This effect of PGE₂ largely results from the promotion of HIF-1 α protein translocation from the cytosol to the nucleus. In addition, we demonstrate that hypoxia-induced HIF-1 α accumulation is suppressed by inhibition of COX-2 activity and restored by the addition of exogenous PGE₂. Finally, we provide evidence that the effects of PGE₂ are mediated, primarily, via the MAP kinase pathway. Our findings demonstrate a critical role for COX-2 and PGE₂ in the regulation of HIF-1 α and VEGF.

EXPERIMENTAL PROCEDURES

Cell Line and Cell Culture—The PC-3ML human prostate cancer cell line, a subline of the PC-3 cell line, was a generous gift from Mark Stearns (Department of Pathology, MCP-Hahnemann University, Philadelphia). It has been characterized as a cell line with a highly invasive and bone-targeting metastatic phenotype (22). Cells were cultured under normoxic conditions (20% O₂, 5% CO₂, 75% N₂) in a humidified Napco incubator at 37 °C. Hypoxic stimulation was produced with an ambient oxygen concentration of 1% (using a controlled incubator with CO₂/O₂ monitoring and CO₂/N₂ gas sources). PC-3ML cells were incubated in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum. Before the treatments with various compounds or hypoxia, cells were washed with PBS, and serum-free medium was replaced overnight. In order to prevent reoxygenation of hypoxic cells, the medium or lysis buffers were pre-equilibrated to the experimental oxygen conditions overnight and added to cells on ice. For reagents, NS398, butaprost, sulprostone, and PGE₂, alcohol were purchased from Cayman Chemical Co. (Ann Arbor, MI); meloxicam is a product of Biomol Inc. (Plymouth Meeting, PA); PD98059, LY294002, and staurosporine were obtained from Calbiochem.

Preparation of Proteins from the Cytosolic or Nuclear Fractions and Immunoblotting—Proteins from the cytosolic and nuclear fractions of the PC-3ML cells were isolated using a commercial kit purchased from Pierce, according to the manufacturer's instructions. The samples were electrophoresed on a 7.5% SDS-polyacrylamide gel, electrophoretically transferred to a polyvinylidene difluoride membrane (PerkinElmer Life Sciences), and incubated with a monoclonal anti-HIF-1 α antibody (Transduction Laboratories, Lexington, KY) overnight at 4 °C. Secondary horseradish peroxidase-linked donkey anti-mouse IgG (Amersham Biosciences) was used. Filters were developed by the enhanced chemiluminescence system (Amersham Biosciences).

RT-PCR—Cells were incubated in serum-free medium. Total RNA was extracted with Trizol Reagent (Invitrogen). cDNA was prepared by incubating 1 μ g of total RNA in 50 mM Tris-HCl (pH 8.3), 75 mM KCl, 3 mM MgCl₂, 10 mM dithiothreitol, and RNase inhibitors with 250 units of reverse transcriptase, 1 μ M of each dNTP, and random primers (0.05 μ M, Invitrogen) for 60 min at 37 °C. The fragment was amplified by PCR using specific primers for HIF-1 α , sense (bp 184–207), 5'-CGGCGC-GAACGACAAGAAAAAGAT-3' and antisense (bp 1327–1350), 5'-TCGTTGGGTGAGGGGAGCATTACA-3'. A set of specific PCR primers for EP receptor subtypes has been prepared as reported by Sheng *et al.* (45): EP₁ fragment, forward (5'-ACCGACCTGGCGGGCCACGTGA-3'; 321–342) and reverse (5'-CGTGAGCGGTGTTGCACACAG-3'; 750–729); EP₂ fragment, forward (5'-TCCAATGACTCCAGTCTGAGG-3'; 750–729) and reverse (5'-TGCATAGATGACAGGCAGCAG-3'); EP₃




Fig. 1. Effect of PGE₂ on HIF-1 α mRNA expression. PC-3ML cells were incubated in serum-free medium and treated with either vehicle or 1 μ M PGE₂ for various times, as indicated. One μ g of total RNA extracted from treated and non-treated cells was reverse-transcribed. The fragment was amplified by specific primers for HIF-1 α or β -actin. The amplified products were visualized on 1.5% agarose gels.

fragment, forward (5'-GATCACCATGCTGCTCACTG-3'; 396–415) and reverse (5'-AGTTATGCGAAGAGC-TAGTCC-3'; 904–884); EP₄ fragment forward (5'-GGGCTGGCTGTCACCGACCTG-3'; 565–585) and reverse (5'-GGTGCGGCGCAT-GAACTGGCG-3'; 1050–1030). Primers for β -actin: forward (5'-GAAGAGCTACGAGCTGCC-3'; 2376–2393) and reverse (5'-TGATCCACATCTGCTGGA-3'; 2927–2944). PCR was initiated in a thermal cycle programmed at 95 °C for 5 min, 94 °C for 30 s, 58 °C for 30 s, 72 °C for 45 s, and amplified with 28 cycles for HIF-1 α and β -actin, and 35 cycles for EP receptor subtypes. The amplified products were visualized on 1.5% agarose gels.

Construction of GFP-tagged HIF-1 α Vector—The vector expressing GFP-tagged HIF-1 α (pEGFP-HIF-1 α) was prepared by fusing HIF-1 α cDNA to the pEGFP (Clontech, Palo Alto, CA). The complete human HIF-1 α cDNA sequence was obtained from GenBankTM (accession number U22431) and amplified by PCR using primers that create the restriction enzyme sites for *Kpn*I and *Bam*HI ends, as described by Wang *et al.* (2). The resulting fragment was subcloned into the *Kpn*I and *Bam*HI site of pEGFP-N1 to generate the GFP-HIF-1 α fusion protein vector.

Transient Transfection and Confocal Laser Scanning Microscopy—PC-3ML cells were cultured in Lab-Tek II chamber slides (Nalge Nunc Co., Naperville, IL) and transiently transfected with either the parental GFP construct (pEGFP, Clontech) or the chimeric pEGFP-HIF-1 α construct using LipofectAMINE 2000 reagent (Invitrogen). After transfection, cells were treated with either vehicle as control or 1 μ M PGE₂, 50 μ M NS398, or hypoxia (1% O₂) for various times. Transfected cells were fixed with 4% formaldehyde in PBS for 10 min at room temperature. Samples were then washed with PBS and covered with mounting medium (Vector Laboratories, Burlingame, CA) to avoid fading. The intensity and the subcellular distribution of fluorescent activity were examined by confocal laser scanning microscopy (Leica Lasertechnik, Heidelberg, Germany).

RESULTS

PGE₂ Has No Effect on HIF-1 α mRNA Expression—Previous reports (21) have suggested that PGE₂ plays a role in hypoxia-induced VEGF expression. To determine whether this process is mediated by the regulation of HIF-1 α , we initially examined the effect of PGE₂ on HIF-1 α mRNA expression. RT-PCR, as shown in Fig. 1, revealed that HIF-1 α mRNA expression is not modulated by the addition of PGE₂ in PC-3ML cells.

PGE₂ Stabilizes HIF-1 α Protein Under Both Normoxic and Hypoxic Conditions—HIF-1 α is a short lived protein with a half-life of under 5 min (2, 23). HIF-1 α is ubiquitinated and subjected to proteasomal degradation in non-hypoxic cells (8). Under hypoxic conditions, HIF-1 α ubiquitination and proteasomal degradation are significantly decreased, leading to increased protein levels. We examined HIF-1 α protein expression in PC-3ML cells under normoxic and hypoxic conditions. Western blot analysis with protein samples extracted either from the cytosol or the nucleus revealed that PC-3ML cells expressed a low level of HIF-1 α protein in the cytosol, and a relatively higher level in the nucleus under normoxic conditions. Hypoxia (12 h) did not have a significant effect on the

² X. H. Liu, A. Kirschenbaum, M. Lu, S. Yao, A. Dosoretz, J. F. Holland, and A. C. Levine, unpublished data.




FIG. 2. PGE₂-induced HIF-1 α protein stabilization. PC-3ML cells were cultured in serum-free medium and treated with either 1 μ M PGE₂, or 1% O₂, or combination of PGE₂ (1 μ M) and 1% O₂ for various times as indicated. Proteins in the nuclear and cytosolic fractions were isolated and subjected to Western blot analysis. Twenty μ g of proteins were loaded in each lane. C, control.

total cytosolic protein levels but induced a band shift from low molecular weight to high molecular weight, suggesting an effect on the post-translational modification of HIF-1 α protein in the cytosol. Hypoxia induced a significant increase in HIF-1 α protein levels in the nuclear fraction, suggesting that hypoxia induced HIF-1 α protein translocation from the cytosol to the nucleus in this cell line (Fig. 2).

We next examined the effect of PGE₂ on HIF-1 α protein expression. Fig. 2 demonstrates that PGE₂ up-regulated HIF-1 α levels in both the cytosolic and nuclear fractions in normoxic cells. The PGE₂-induced HIF-1 α protein expression in the cytosol was first noted 2 h after treatment which was prior to the induction observed in the nuclear fraction (4 h). The combination of PGE₂ and hypoxia resulted in greater increases in HIF-1 α protein levels, particularly in the nuclear fraction, than those seen with either treatment alone. Of note, the combination of hypoxia and 1 μ M PGE₂ induced a band shift in the cytosolic fraction, which, again, may represent an effect on the post-translational modification of the protein (Fig. 2). These data indicate that PGE₂ and hypoxia act both independently and synergistically to increase HIF-1 α protein levels and nuclear localization in PC-3 ML human prostate cancer cells.

PGE₂-induced Nuclear Localization of HIF-1 α Protein—Previous studies (6) have determined that endogenous HIF-1 α translocates to the nucleus in hypoxic cells. Nuclear translocation of HIF-1 α is necessary for its activation and its transcriptional activation of a variety of hypoxia-regulated genes, including VEGF. In addition, the translocation of HIF-1 α protein to the nucleus has been proposed recently (24) as a regulatory step involved in its stabilization. Our data from Western blotting indicated that both hypoxia and PGE₂ significantly increased HIF-1 α protein levels, particularly in the nuclear fraction. Therefore, we investigated the possibility that PGE₂ promotes HIF-1 α protein nuclear translocation independent of hypoxia using a nucleo-cytosolic trafficking assay. We generated a pEGFP-HIF-1 α vector that expresses GFP-tagged HIF-1 α protein. The vector was transiently transfected into PC-3ML cells. The cells were then treated with 1 μ M PGE₂ for various times under normoxic conditions, and the intracellular localization of the GFP-HIF-1 α fusion protein was visualized using a laser scanning confocal microscope. Consistent with the results obtained by Western blotting, treatment with 1 μ M PGE₂ induced a time-dependent nuclear accumulation of the protein (Fig. 3).

The Effect of PGE₂ on HIF-1 α Is Mediated by Specific EP Receptor Subtypes—The family of EP receptors consists of four subtypes of G protein-coupled receptors, designated EP₁, EP₂, EP₃, and EP₄. Through these receptors, PGE₂ modulates a variety of physiological and pathological functions (25). We next examined the expression of EP receptor subtypes in PC-3ML cells by RT-PCR using specific oligonucleotide primers reported by Sheng *et al.* (26). As demonstrated in Fig. 4A, EP₂, EP₃, and EP₄ are clearly expressed in PC-3ML cells. In con-




FIG. 3. PGE₂-induced nuclear translocation of HIF-1 α protein. PC-3ML cells were transiently transfected with the chimeric pEGFP-HIF-1 α construct. After transfection, cells were cultured under normoxic conditions and treated with either vehicle as control (a) or 1 μ M PGE₂ for 4 (b), 6 (c), 8 (d), 12 (e), and 16 h (f). Cells were then fixed with 4% formaldehyde in PBS and covered by mounting medium. The intensity and subcellular localization of pGFP-HIF-1 α were examined using a laser scanning confocal microscope.

trast, EP₁ mRNA was undetectable in this cell line. To evaluate the functional role of EP receptor subtypes in PC-3ML cells, we tested the effects of butaprost (a selective EP₂ receptor agonist), sulprostone (a selective EP₃ receptor agonist), and PGE₁ alcohol (a selective EP₄ receptor agonist) (25) on HIF-1 α protein expression under normoxic conditions. Although the EP₃ receptor agonist sulprostone had no detectable effect (data not shown), both butaprost (an EP₂ receptor agonist) and PGE₁ alcohol (an EP₄ receptor agonist) significantly stimulated the expression level of HIF-1 α in both the cytosolic and nuclear fractions (Fig. 4B), mimicking the effects of PGE₂ alone. The data demonstrate that PGE₂-induced up-regulation of HIF-1 α protein is mediated through the EP₂ and EP₄ receptor signaling pathways in this cell line.

The Roles of MAPK and PI3K/AKT in PGE₂-induced HIF-1 α Expression—We next determined the possible involvement of several intracellular kinase pathways in PGE₂-induced HIF-1 α expression. As shown in Fig. 5A, Western blot analysis demonstrated that PD98059, a MAPK inhibitor (50 μ M), had no effect on basal HIF-1 α expression but did significantly suppress PGE₂-induced up-regulation of HIF-1 α protein expression in a dose-dependent fashion (Fig. 5B). It was notable that whereas PD98059 inhibited both high and low molecular weight bands of HIF-1 α protein in the nucleus, it specifically suppressed the higher molecular weight band of the protein in the cytosolic fraction. These results indicate that inhibition of HIF-1 α phosphorylation in the cytosol may prevent its nuclear translocation. LY294002, a PI3K inhibitor, strongly inhibited basal HIF-1 α nuclear accumulation but only partially inhibited PGE₂-inducible nuclear and cytosolic HIF-1 α protein levels. Staurosporine, a protein kinase C inhibitor, had no effect on either basal and PGE₂-induced HIF-1 α expression in both the nuclear and cytosolic fractions (Fig. 5A). These




FIG. 4. Determination of the role of EP receptor subtypes. *A*, mRNA expression of PGE₂ receptor subtypes was examined using RT-PCR. One μ g of total RNA extracted from PC-3ML cells was subjected to reverse-transcription and amplified by specific primers for EP₁, EP₂, EP₃, and EP₄ for 35 cycles. The amplified products were visualized on 1.5% agarose gels. *M*, 1 kb plus DNA ladder. *B*, the effect of EP receptor agonists on HIF-1 α protein expression. PC-3ML cells were incubated in serum-free medium and treated with either vehicle (lane 1), 1 μ M PGE₂ (lane 2), 0.1 μ M PGE₁ alcohol (lane 3), or 10 μ M butaprost (lane 4) for 4 h. Proteins were extracted from the nuclear or cytosolic fractions and subjected to Western blot analysis.




FIG. 5. The effects of kinase inhibitors on PGE₂-induced HIF-1 α stabilization. *A*, PC-3ML cells were pretreated with 50 μ M PD98059, 5 μ M LY294002, or 20 nM staurosporine for 20 h, and incubations were continued with or without 1 μ M PGE₂ for an additional 4 h. Proteins in the nuclear and cytosolic fractions were isolated and subjected to Western blot analysis. *B*, cells were pretreated with various concentrations of PD98059 as indicated for 20 h prior to 1 μ M PGE₂ treatment for 4 h. Proteins in the nuclear and cytosolic fractions were then isolated and subjected to Western blot analysis.

results demonstrate that the MAP kinase inhibitor (PD98059) specifically inhibits PGE₂-induced stabilization and nuclear localization of HIF-1 α in this cell line, whereas




FIG. 6. The effects of COX-2 inhibitors on hypoxia-induced nuclear accumulation of HIF-1 α . *A*, PC-3ML cells were cultured in serum-free medium for 24 h prior to various treatments as follows: lane 1, vehicle only as control; lane 2, 1 μ M PGE₂ for 4 h; lane 3, 1% O₂ for 12 h; lane 4, 10 μ M meloxicam for 48 h; lane 5, 10 μ M meloxicam for 44 h followed by 1 μ M PGE₂ for an additional 4 h; lane 6, 10 μ M meloxicam for 36 h followed by 1% O₂ for 12 h; lane 7, 10 μ M meloxicam plus 10 μ M PGE₂ for 36 h prior to 1% O₂ treatment for 12 h. Proteins in the nuclear and cytosolic fractions were then isolated and subjected to Western blot analysis. *B*, NS398-suppressed basal and hypoxia-induced nuclear relocalization of HIF-1 α protein. PC-3ML cells were transiently transfected with the chimeric pEGFP-HIF-1 α construct. After transfection, cells were treated with vehicle as control (a), 50 μ M NS398 for 2 days under normoxic conditions (b), hypoxia (1% O₂) for 12 h (c), and pretreated with NS398 (50 μ M) for 36 h under normoxic conditions followed by hypoxia (1% O₂) treatment for an additional 12 h (d). Cells were then fixed with 4% formaldehyde in PBS and covered by mounting medium. The intensity and subcellular localization of pEGFP-HIF-1 α were examined using a laser scanning confocal microscope.

the PI3K inhibitor (LY294002) acts non-specifically to inhibit both the basal and PGE₂-induced effects on the protein.

Inhibition of COX-2 Activity Suppresses Hypoxia-induced HIF-1 α Nuclear Accumulation—We reported previously that NS398, a selective COX-2 inhibitor, prevents VEGF up-regulation in response to cobalt chloride-simulated hypoxia (21). Similar results were observed when the same cell line was exposed to true hypoxia (1% O₂). We tested whether this effect of the COX-2 inhibitor is due to inhibition of hypoxic effects on HIF-1 α protein expression. However, NS398, in addition to its COX-2 inhibitory activity, has also been reported to inhibit MAPK activity directly (27). Therefore, we examined the effect of another selective COX-2 inhibitor, meloxicam, on HIF-1 α protein expression. Meloxicam has not been reported to have any direct effect on MAPK activity. As shown in Fig. 6A, Western blotting confirmed that both PGE₂ and hypoxia significantly up-regulated HIF-1 α protein levels. In the nuclear fraction, pretreatment of cells with meloxicam (10 μ M) for 2 days inhibited both the basal and hypoxia-induced accumulation of the protein in both the nuclear and cytosolic fractions. These inhibitory effects were predominantly observed in the higher molecular weight bands. Fig. 6A also demonstrates that the addition of PGE₂ completely reversed the inhibitory effects of

meloxicam on hypoxia-induced up-regulation of HIF-1 α protein.

We performed a nucleo-cytosolic trafficking assay (laser scanning of confocal microscopy) using a GFP-tagged HIF-1 α system to confirm the results noted on immunoblotting. Fig. 6B demonstrates that COX-2 inhibition prevents both basal and hypoxia-induced nuclear accumulation of HIF-1 α protein. These results demonstrate that PGE₂ production via the COX-2-catalyzed pathway plays a critical role in hypoxia-stimulated effects on HIF-1 α protein.

DISCUSSION

There is ample evidence that COX-2 overexpression contributes to carcinogenesis and that COX-2 disruption can both prevent and treat a variety of solid tumors (14, 16, 28–30). COX-2 inhibitors have demonstrated direct effects on tumor cells (induction of apoptosis) (31, 32). In addition to these direct effects, prostaglandins derived from COX-2 exert indirect effects on tumor growth via the promotion of tumor angiogenesis (18–20, 33–35). COX-2 effects on angiogenesis are mediated, at least in part, by modulation of VEGF expression (18, 20). Several studies (20, 36) have shown that inhibition of COX-2 activity (via genetic knockout or pharmacologic inhibitors) results in decreased tumor and stromal VEGF levels with resultant impairment of tumor growth and angiogenesis. PGE₂, one of the major eicosanoid products of the COX-2-catalyzed reaction, has also been specifically implicated in the promotion of VEGF expression and tumor angiogenesis in a variety of cell types (37, 38).

Our previous studies with human prostate cancer cells *in vitro* delineated one cell line, PC-3 ML, in which VEGF levels were dramatically up-regulated by cobalt chloride-simulated hypoxia. Administration of a selective COX-2 inhibitor prevented hypoxia-simulated up-regulation of VEGF, and the co-administration of PGE₂ restored the ability of hypoxia to increase VEGF in the presence of the COX-2 inhibitor (21). In the current report, we studied the effects of true hypoxia and PGE₂ on the expression of the hypoxia-inducible factor-1 α (HIF-1 α), a master oxygen sensor, in the same prostate cancer cell line. PGE₂ had no effect on HIF-1 α mRNA levels but did modulate its protein expression. The lack of effect of PGE₂ on transcriptional activation of HIF-1 α was not surprising in view of the fact that hypoxic regulation of HIF-1 α is also primarily determined by stabilization of HIF-1 α protein, which is otherwise rapidly degraded in oxygenated cells (23).

The mechanisms underlying hypoxic effects on the ubiquitin-ligase complex responsible for HIF-1 α protein degradation have been well elucidated recently by the identification of an oxygen- and iron-dependent proline hydroxylase responsible for the post-translational modification of HIF-1 α . Proline hydroxylation of the oxygen-dependent domain of HIF-1 α results in recognition of the protein by pVHL and subsequent ubiquitination and degradation (39, 41). In addition, hypoxia induces the nuclear translocation of HIF-1 α protein (6). The precise mechanisms underlying this nuclear accumulation and its role in HIF-1 α stabilization and activation have not yet been established. Nuclear targeting of the protein has been proposed as a regulatory step whereby HIF-1 α escapes from proteasomal degradation (11, 24). In addition, nuclear localization of HIF-1 α has been shown to be essential, although not sufficient, for activation of the protein (6, 11).

In the current report, we provide evidence that PGE₂ alone, under normoxic conditions, increases HIF-1 α protein levels. In addition, PGE₂ potentiates hypoxia-induced HIF-1 α expression and nuclear localization. Moreover, inhibition of COX-2 activity significantly suppressed hypoxia-induced nuclear accumulation of HIF-1 α protein, as demonstrated by Western blotting

and a GFP-tagged HIF-1 α system. Finally, PGE₂ addition to meloxicam-treated cells restored the ability of hypoxia to induce HIF-1 α nuclear accumulation, establishing a specific role for PGE₂ in this process.

We reported that PC-3ML cells express relatively high constitutive levels of COX-2 (21) but not COX-1 (data not shown), suggesting that PGE₂ production is mainly derived from COX-2 activity in this cell line. The selective COX-2 inhibitors decreased HIF-1 α nuclear protein levels in PC-3ML cells under both normoxic and hypoxic conditions. Concomitant addition of PGE₂ to meloxicam-treated hypoxic cells completely reversed the effects of the selective COX-2 inhibitor. In addition, we examined the possible effects of other PGs that are also derived from the COX-2-catalyzed pathway. Our results indicate that neither PGD₂, PGI₂, nor PGF_{2 α} significantly modulate HIF-1 α protein expression or reverse the effects of the COX-2 inhibitors in PC-3ML cells (data not shown). These data support our conclusion that PGE₂ production via the COX-2-catalyzed pathway specifically mediates hypoxic effects on HIF-1 α protein in this cell line.

Several reports demonstrated that hypoxia induces the phosphorylation of HIF-1 α by p42/p44 MAPK (also called extracellular signal-regulated kinase, Erk1/2), which increases both HIF-1 α nuclear localization and transcriptional activity (10–13, 42). In addition, PGE₂ has been shown to enhance directly MAPK activity in colon cancer cells (26). In the present study, we observed that hypoxia and PGE₂, alone and in combination, promote the nuclear accumulation of HIF-1 α protein. Both hypoxia and PGE₂ also induce a higher molecular weight HIF-1 α band in the cytosol, which may represent an effect on post-translational modification, presumably phosphorylation, of the protein. This induction was blocked by PD98059 (a MAP kinase inhibitor) and COX-2 inhibitors. These results suggest that PGE₂ induces phosphorylation of HIF-1 α protein in the cytosol and imply that this phosphorylation, presumably by the MAP kinase (Erk1/2), is a prerequisite step for nuclear translocation of the protein and necessary for its stabilization. Consistent with these findings, COX inhibitors were recently shown to inhibit cancer cell growth and T cell activation by inhibiting the MAPK pathway (43–45).

The PI3K/AKT signaling pathway was demonstrated previously (46, 47) to be involved in hypoxia-induced effects on VEGF and HIF-1 α expression. Moreover, recent reports (26, 31) reveal that PGE₂, acting via the prostaglandin EP₄ receptor, activates both the PI3K/AKT and Erk1/2 pathways, resulting in increased growth, motility, and resistance to apoptosis in cancer cells. Our data, however, demonstrate that LY294002, a potent PI3K inhibitor, completely inhibited basal expression patterns of HIF-1 α protein but only partially inhibited the PGE₂ effects on the protein. These results indicate an important role for PI3K/Akt pathway in the maintenance of basal HIF-1 α protein expression but fail to demonstrate a specific role for PI3K/Akt in the PGE₂-induced nuclear accumulation of HIF-1 α protein.

The effects of PGE₂ are mediated through a specific family of transmembrane G protein-coupled receptors (EP receptors) (25). Three of the four EP receptor subtypes (EP₂, EP₃, and EP₄) are expressed in PC-3ML cells. Our data indicate that both the EP₂ and EP₄ receptor subtypes mediate the observed PGE₂ effects on HIF-1 α regulation in this cell line.

Prostate cancer is the most common cancer and second leading cause of cancer deaths in males in the United States. A number of clinical investigations have demonstrated a relationship between the degree of neovascularization and cancer grade (48), metastatic behavior (49), and cancer-specific survival (50). Prostate cancer cells have been reported to overex-

press COX-2 and produce elevated levels of PGE₂ (15, 51). We reported previously (21) that the PC-3ML cell line, an androgen-insensitive, highly invasive and metastatic human prostate cancer cell line, expresses high constitutive and hypoxia-inducible levels of COX-2. In addition, this cell line is distinguished from other prostate cancer cell lines by its ability to dramatically up-regulate VEGF (5–6-fold) in response to cobalt chloride-simulated hypoxia, which is suppressed by a selective COX-2 inhibitor (21). In the current report, we demonstrate further that PGE₂ production via the COX-2-catalyzed pathway plays critical roles in the hypoxic regulation of HIF-1 α in this cell line.

Intratumoral hypoxia cannot be manipulated. Hypoxia regulates the expression of the α -subunit of HIF, the primary transcription factor involved in the hypoxic response. HIF induces the expression of genes essential for oxygen homeostasis and angiogenesis including VEGF, erythropoietin, tyrosine hydroxylase, inducible nitric-oxide synthase, and glycolytic enzymes. Our data demonstrate that selective COX-2 inhibitors prevents hypoxic up-regulation of HIF-1 α in a human prostate cancer cell line. Given the seminal role of HIF-1 α in the regulation of genes associated with cancer cell survival and tumor angiogenesis, our data provide a rationale for the use of COX-2 inhibitors as both anti-tumor and anti-angiogenic therapy in the treatment of prostate cancer.

Acknowledgments—We thank the Microscopy Shared Research Facility at Mount Sinai School of Medicine for technical assistance and Dr. Mark Stearns for the PC-3ML cell line. Confocal laser scanning microscopy was performed at the Mount Sinai School of Medicine, Microscopy Center, and was supported by National Institutes of Health Shared Instrumentation Grant 1 S10 RR09145-01 and National Science Foundation Major Research Instrumentation Grant DBI-9724504.

REFERENCES

- Folkman, J. (1992) *J. Natl. Cancer Inst.* **82**, 4–7
- Wang, G. L., Jiang, B. H., Rue, E. A., and Semenza, G. L. (1995) *Proc. Natl. Acad. Sci. U. S. A.* **92**, 5510–5514
- Shima, D. T., Kuroki, M., Deutsch, U., Ng, Y. S., Adamis, A. P., and D'Amore, P. A. (1994) *J. Biol. Chem.* **271**, 3877–3883
- Kung, A., Wang, S., Kico, J. M., Kaelin, W. G., and Livingston, D. M. (2000) *Nat. Med.* **6**, 1335–1340
- Carmeliet, P., Dor, Y., Herbert, J. M., Fukumura, D., Brusselmans, K., Dewerchin, M., Neeman, M., Bono, F., Abramovitch, R., Maxwell, P., Koch, C. J., Ratcliffe, P., Moons, L., Jain, R. K., Collen, D., Keshner, E., and Keshet, E. (1998) *Nature* **394**, 485–490
- Kallio, P. J., Okamoto, K., O'Brien, S., Carrero, P., Makino, Y., Tanaka, H., and Poellinger, L. (1998) *EMBO J.* **17**, 6573–6586
- Fang, J. M., Yan, L., Shing, Y., and Moses, M. A. (2001) *Cancer Res.* **61**, 5731–5735
- Maxwell, P. H., Wiesener, M. S., Chang, G. W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., and Ratcliffe, P. J. (1999) *Nature* **399**, 271–275
- Yu, F., White, S. B., Zhao, Q., and Lee, F. S. (2001) *Cancer Res.* **61**, 4136–4142
- Semenza, G. L. (2001) *Curr. Opin. Cell Biol.* **13**, 167–171
- Richard, D. E., Berra, E., and Pouyssegur, J. (1999) *Biochem. Biophys. Res. Commun.* **266**, 718–722
- Berra, E., Milanini, J., Richard, D. E., Gall, M. L., Vinals, F., Gothie, E., Roux, D., Pages, G., and Pouyssegur, J. (2000) *Biochem. Pharmacol.* **60**, 1171–1178
- Richard, D. E., Berra, E., Gothie, E., Roux, D., and Pouyssegur, J. (1999) *J. Biol. Chem.* **274**, 32631–32637
- Taketo, M. M. (1998) *J. Natl. Cancer Inst.* **90**, 1609–1620
- Tjandrawinata, R. R., Dahiya, R., and Hughes-Fulford, M. (1997) *Br. J. Cancer* **75**, 1111–1118
- Dannenberg, A. J., Altorki, N. D., Boyle, J. O., Dang, C., Howe, L. R., Weksler, B. B., and Subbaramaiah, K. (2001) *Lancet Oncol.* **2**, 544–551
- Schmedtje, J. F., Jr., Ji, Y. S., Liu, W. L., DuBois, R. N., and Runge, M. S. (1997) *J. Biol. Chem.* **272**, 601–608
- Tsuji, M., Kawano, S., Tsuji, S., Sawaoka, H., Hori, M., and DuBois, R. N. (1998) *Cell* **93**, 705–716
- Form, D. M., and Auerbach, R. (1983) *Proc. Soc. Exp. Biol. Med.* **172**, 214–218
- Liu, X. H., Kirschenbaum, A., Yao, S., Lee, R., Holland, J. F., and Levine, A. C. (2000) *J. Urol.* **164**, 820–825
- Liu, X. H., Kirschenbaum, A., Yao, S., Stearns, M. E., Holland, J. F., Claffey, K., and Levine, A. C. (1999) *Clin. Exp. Metastasis* **17**, 687–694
- Wang, M., and Stearns, M. E. (1991) *Differentiation* **48**, 115–125
- Huang, L. E., Gu, J., Schau, M., and Bunn, H. F. (1998) *Proc. Natl. Acad. Sci. U. S. A.* **95**, 7987–7992
- Tanimoto, K., Makino, Y., Pereira, T., and Poellinger, L. (2000) *EMBO J.* **19**, 4298–4309
- Breyer, M. D., and Breyer, R. M. (2000) *Am. J. Physiol.* **279**, F12–F23
- Sheng, H. M., Shao, M., Washington, K. M., and DuBois, R. N. (2001) *J. Biol. Chem.* **276**, 18075–18081
- Jones, M. K., Wang, H., Peskar, B. M., Levin, E., Itani, R. M., Sarfeh, I. J., and Tarnawski, A. S. (1999) *Nat. Med.* **5**, 1418–1423
- Williams, C. S., Mann, M., and DuBois, R. N. (1999) *Oncogene* **18**, 7908–7916
- Reddy, B. S., Hirose, Y., Lubet, R., Steele, V., Kelloff, G., Paulson, S., Seibert, K., and Rao, C. V. (2000) *Cancer Res.* **60**, 293–297
- DuBois, R. N., Abramson, S. B., Crofford, L., Gupta, R. A., Simon, L. S., Van DePutte, L. B. A., and Lipsky, P. E. (1998) *FASEB J.* **12**, 1063–1073
- Hsu, A.-L., Ching, T.-T., Wang, D.-S., Song, X., Rangnekar, V. M., and Chen, C.-S. (2000) *J. Biol. Chem.* **275**, 11397–11403
- Liu, X. H., Yao, S., Kirschenbaum, A., and Levine, A. C. (1998) *Cancer Res.* **58**, 4245–4249
- Sawaoka, H., Tsuji, S., Tsujii, M., Gunawan, E. S., Sasaki, Y., Kawano, S., Hori, M. (1999) *Lab. Invest.* **79**, 1469–1477
- Masferrer, J. L., Leahy, K. M., Koki, A. T., Sweifel, B. S., Sterrle, S. L., Woerner, B. M., Edwards, D. A., Flikinger, A. G., Moore, R. J., and Siebert, K. (2000) *Cancer Res.* **60**, 1306–1311
- Gately, S. (2000) *Cancer Metastasis Rev.* **19**, 19–27
- Williams, C. S., Tsujii, M., Reese, J., Dey, S. K., and DuBois, R. N. (2000) *J. Clin. Invest.* **105**, 1589–1594
- Harada, S., Nagy, J. A., Sullivan, K. A., Thomas, K. A., Endo, N., Rodan, G. A., and Rodan, S. B. (1994) *J. Clin. Invest.* **93**, 2490–2496
- Hoper, M. M., Voelkel, N. F., Bates, T. O., Allard, J. D., Horan, M., Shepherd, D., and Tuder, R. M. (1997) *Am. J. Respir. Cell Mol. Biol.* **17**, 748–756
- Bruick, R. K., and McKnight, S. L. (2001) *Science* **294**, 1337–1340
- Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., Asara, J. M., Lane, W. S., and Kaelin, W. G., Jr. (2001) *Science* **292**, 464–468
- Jaakola, P., Mole, D. R., Tian, Y. M., Wilson, M. I., Gielbert, J., Gaskell, S. J., von Kriegsheim, A., Hebestreit, H. F., Mukherji, M., Schofield, C. J., Maxwell, P. H., Pugh, C. W., and Ratcliffe, P. J. (2001) *Science* **292**, 468–472
- Berra, E., Roux, D., Richard, D. E., and Pouyssegur, J. (2001) *EMBO Rep.* **21**, 1–6
- Husain, S. S., Szabo, I. L., Pai, R., Soreghan, B., Jones, M. K., and Tarnawski, A. S. (2001) *Life Sci.* **69**, 3045–3054
- Paccanis, R., Boncristiano, M., Olivieri, C., D'Elia, M. M., Del Prete, G., and Baldari, C. T. (2002) *J. Biol. Chem.* **277**, 1509–1513
- Sheng, H., Shao, J., Morrow, J. D., Beauchamp, R. D., and DuBois, R. N. (1998) *Cancer Res.* **58**, 362–366
- Zhong, H., Chiles, K., Feldser, D., Laughner, E., Hanrahan, C., Georgescu, M. M., Simons, J. W., and Semenza, G. L. (2000) *Cancer Res.* **60**, 1541–1545
- Mazure, N. M., Chen, E. Y., Laderoute, K. R., and Giaccia, A. J. (1997) *Blood* **90**, 3322–3331
- Brawer, M. K., Deering, R. E., Brown, M., Preston, S. D., and Bigler, S. A. (1994) *Cancer (Phila.)* **73**, 678–687
- Weidner, N., Carroll, P. R., Flax, J., Blumenfeld, W., and Folkman, J. (1993) *Am. J. Pathol.* **143**, 401–409
- Lissbrant, I. F., Stattin, P., Damber, J. E., and Bergh, A. (1997) *Prostate* **33**, 38–45
- Kirschenbaum, A., Klausner, A. P., Lee, R., Unger, P., Yao, S., Liu, X. H., and Levine, A. C. (2000) *Urology* **56**, 671–675